These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1515247)

  • 21. Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin.
    Gralla RJ; Rittenberg C; Peralta M; Lettow L; Cronin M
    Oncology; 1996 Jun; 53 Suppl 1():86-91. PubMed ID: 8692558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis.
    Sekine I; Nishiwaki Y; Kakinuma R; Kubota K; Hojo F; Matsumoto T; Ohmatsu H; Yokozaki M; Kodama T
    Jpn J Clin Oncol; 1996 Jun; 26(3):164-8. PubMed ID: 8656557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
    Support Care Cancer; 1994 May; 2(3):167-70. PubMed ID: 8032702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial.
    Kris MG; Gralla RJ; Clark RA; Tyson LB; Groshen S
    Cancer; 1987 Dec; 60(11):2816-22. PubMed ID: 3315176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination.
    Roila F
    Oncology; 1993; 50(3):163-7. PubMed ID: 8459986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of Cisplatin-Doxorubicin and high-dose Ifosfamide over 48, 24, and 120 hours.
    Forni C; Loro L; Mazzei T; Beghelli C; Biolchini A; Tremosini M; Triggiani A; Bacci G
    Cancer Nurs; 2003 Aug; 26(4):331-4. PubMed ID: 12886124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research.
    Ann Oncol; 1994 Sep; 5(7):585-9. PubMed ID: 7993832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study.
    Roila F; Boschetti E; Tonato M; Basurto C; Bracarda S; Picciafuoco M; Patoia L; Santi E; Penza O; Ballatori E
    Am J Clin Oncol; 1991 Jun; 14(3):238-42. PubMed ID: 2031511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy.
    Strum SB; McDermed JE; Liponi DF
    J Clin Oncol; 1985 Feb; 3(2):245-51. PubMed ID: 4038511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
    Navari RM; Reinhardt RR; Gralla RJ; Kris MG; Hesketh PJ; Khojasteh A; Kindler H; Grote TH; Pendergrass K; Grunberg SM; Carides AD; Gertz BJ
    N Engl J Med; 1999 Jan; 340(3):190-5. PubMed ID: 9917226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.
    Warr D; Wilan A; Venner P; Pater J; Kaizer L; Laberge F; Latreille J; Stewart D; O'Connell G; Osoba D
    Eur J Cancer; 1992; 29A(1):33-6. PubMed ID: 1332737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
    Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
    Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer.
    Passalacqua R; Cocconi G; Caminiti C; Silingardi V; Bella MA; Bichisao E; Michiara M; Malavasi V; Donati D; Di Costanzo F; Rocca A; Di Sarra S; Scaglione F; Fraschini F
    J Clin Oncol; 1997 Jun; 15(6):2467-73. PubMed ID: 9196163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
    Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Hansen O; Sörensen BT; Räisänen I; van Oosterom AT; de Bruijn KM
    Cancer; 1994 Jan; 73(2):445-54. PubMed ID: 8293412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].
    Nino S; Umehara H; Inoue I; Tamura T; Sasaki Y; Sakurai M; Shinkai T; Eguchi K; Saijo N; Suemasu K
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2881-4. PubMed ID: 3310905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
    Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
    Campos D; Pereira JR; Reinhardt RR; Carracedo C; Poli S; Vogel C; Martinez-Cedillo J; Erazo A; Wittreich J; Eriksson LO; Carides AD; Gertz BJ
    J Clin Oncol; 2001 Mar; 19(6):1759-67. PubMed ID: 11251007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.
    J Clin Oncol; 1998 Sep; 16(9):2937-42. PubMed ID: 9738561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin.
    Stephens SH; Silvey VL; Wheeler RH
    Cancer; 1990 Aug; 66(3):443-6. PubMed ID: 2194642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.